[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100605305":3},{"organization":4,"outcomesModule":7,"designInfo":13,"detailedDescription":11,"studyPopulation":11,"armGroups":22,"interventions":36,"overallOfficials":11,"centralContacts":11,"locations":11,"responsibleParty":45,"collaborators":11,"id":47,"slug":11,"hasResults":48,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":11,"eligibilityCriteria":52,"healthyVolunteers":48,"sex":53,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":11,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":68,"whyStopped":11,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":11},{"fullName":5,"class":6},"Onconic Therapeutics Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":11,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"The proportion of days with no heartburn",null,"The proportion of days with no heartburn for 24 hours (daytime\u002Fnighttime) over 4 weeks",{"allocation":14,"interventionModel":15,"interventionModelDescription":11,"primaryPurpose":16,"observationalModel":11,"timePerspective":11,"maskingInfo":17},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":18,"maskingDescription":11,"whoMasked":19},"DOUBLE",[20,21],"PARTICIPANT","INVESTIGATOR",[23,28,31],{"label":24,"type":25,"description":11,"interventionNames":26},"Group 1: JP-1366 A mg + Placebo","EXPERIMENTAL",[27],"Drug: JP-1366 + placebo",{"label":29,"type":25,"description":11,"interventionNames":30},"Group 2: JP-1366 B mg + Placebo",[27],{"label":32,"type":33,"description":11,"interventionNames":34},"Placebo + Placebo","PLACEBO_COMPARATOR",[35],"Drug: Placebo + Placebo",[37,42],{"type":38,"name":39,"description":40,"armGroupLabels":41,"otherNames":11},"DRUG","JP-1366 + placebo","taking JP-1366 + placebo",[24,29],{"type":38,"name":32,"description":43,"armGroupLabels":44,"otherNames":11},"taking placebo + placebo",[32],{"type":46,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100605305",false,"NCT07160790","Phase 3 Study of JP-1366: Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux Disease","Efficacy and Safety of JP-1366 in Patients With Non-erosive Gastroesophageal Reflux(NERD) Disease: Double-blind, Randomized","Inclusion Criteria:\n\n* Subjects who have experienced both heartburn and acid regurgitation\n* Subjects in whom no mucosal breaks were observed on upper GI endoscopy at Visit 1 by LA Classification\n* Subjects who fully understand this clinical trial and voluntarily signed the informed consent form\n\nExclusion Criteria:\n\n* Subjects who have significant gastrointestinal diseases or procedures affecting the esophagus, stomach, or duodenum\n* Subjects who have a history of recent substance abuse, malignancy, systemic autoimmune or immune deficiency diseases, refractory response to PPI\u002FP-CAB, hypersensitivity to study drugs, genetic metabolic disorders, or significant psychiatric conditions.\n* Subjects who showed clinically significant abnormalities in laboratory tests\n* Positive result in the H. pylori test\n* Pregnant or breast-feeding women\n* Subjects who require hospitalization are scheduled to undergo surgery during the study period, or have undergone major surgery requiring general anesthesia\n* Other people deemed unsuitable for participation in this study according to the medical opinion of the investigator","ALL","19 Years","75 Years",{"count":57,"type":58},321,"ESTIMATED","INTERVENTIONAL",[61],"PHASE3","This study aims to evaluate the efficacy and safety of JP-1366 in Patients with NERD",[64],"Non-erosive Gastroesophageal Reflux Disease",[66,67],"Non-erosive Reflux Disease","Non-Erosive Gastro-Esophageal Reflux Disease","NOT_YET_RECRUITING","2025-08-29",{"date":71,"type":72},"2025-09-08","ACTUAL",{"date":74,"type":58},"2025-09-02",{"date":76,"type":58},"2026-06-30",{"name":5,"class":6}]